Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Epigenetic changes in patients with multiple sclerosis.
A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (LIBRETTO)
Motor skill learning requires active central myelination.
Microglia activation is associated with IFN-α induced depressive-like behavior.
Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.
Safety issue puts daclizumab in doubt for MS
The Vitamin D to Ameliorate Multiple Sclerosis (VIDAMS) trial: study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis.
Specific peripheral B cell tolerance defects in patients with multiple sclerosis.
Apitope Announces Positive Results from Clinical Trial of ATX-MS-1467 in Relapsing Multiple Sclerosis
Receptos Reports Positive Phase 2 Results for TOUCHSTONE Trial of RPC1063 in Ulcerative Colitis
Design, engineering, and production of human recombinant t cell receptor ligands derived from human leukocyte antigen DR2.
Epigenetic mechanisms in multiple sclerosis and the major histocompatibility complex (MHC).
Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome.
Pediatric multiple sclerosis.
The INCAT disability score: A critical analysis of its measurement properties.
Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection.
US top court denies Israel's Teva Pharmaceuticals stay in Copaxone patent fight
Disease-modifying treatments for progressive multiple sclerosis.
Prolonged Remission in Neuromyelitis Optica Following Cessation of Rituximab Treatment.
Activation of axonal Kv7 channels in human peripheral nerve by flupirtine but not placebo - therapeutic potential for peripheral neuropathies: results of a randomised controlled trial.
Saccadic intrusions: review and update.
Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis.
IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.

Pages